143 related articles for article (PubMed ID: 19309406)
1. Interpretation of diffuse Cdx2 expression in endometrioid adenocarcinoma in the absence of morules.
Wani Y
Histopathology; 2009 Mar; 54(4):495-7. PubMed ID: 19309406
[No Abstract] [Full Text] [Related]
2. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2.
Houghton O; Connolly LE; McCluggage WG
Histopathology; 2008 Aug; 53(2):156-65. PubMed ID: 18752499
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Cdx2 expression in endometrial lesions with squamous differentiation: important role of Cdx2 in squamous morula formation.
Wani Y; Notohara K; Saegusa M; Tsukayama C
Hum Pathol; 2008 Jul; 39(7):1072-9. PubMed ID: 18495206
[TBL] [Abstract][Full Text] [Related]
4. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
5. Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma.
Xiong Y; Xiong YY; Zhou YF
Eur J Gynaecol Oncol; 2010; 31(2):160-4. PubMed ID: 20527231
[TBL] [Abstract][Full Text] [Related]
6. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.
Singh M; Spoelstra NS; Jean A; Howe E; Torkko KC; Clark HR; Darling DS; Shroyer KR; Horwitz KB; Broaddus RR; Richer JK
Mod Pathol; 2008 Jul; 21(7):912-23. PubMed ID: 18487993
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.
Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959
[TBL] [Abstract][Full Text] [Related]
8. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
Silva EG; Deavers MT; Bodurka DC; Malpica A
Int J Gynecol Pathol; 2006 Jan; 25(1):52-8. PubMed ID: 16306785
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic study of endometrial dedifferentiated endometrioid adenocarcinoma: a case report.
Shen Y; Wang Y; Shi Y; Liu J; Liu Y
Int J Clin Exp Pathol; 2012; 5(1):77-82. PubMed ID: 22295150
[TBL] [Abstract][Full Text] [Related]
10. 'Minimal deviation' endometrioid carcinoma with oncocytic change of the endometrium.
Mai KT; Yazdi HM; Boone SA
Arch Pathol Lab Med; 1995 Aug; 119(8):751-4. PubMed ID: 7544107
[TBL] [Abstract][Full Text] [Related]
11. [Application of immunohistochemistry in differential diagnosis of endometrial carcinoma].
Wu HW; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):784-8. PubMed ID: 23302346
[No Abstract] [Full Text] [Related]
12. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.
Shaco-Levy R; Sharabi S; Piura B; Sion-Vardy N
Acta Obstet Gynecol Scand; 2008; 87(8):868-74. PubMed ID: 18607832
[TBL] [Abstract][Full Text] [Related]
13. Clusterin immunoexpression is associated with early stage endometrial carcinomas.
Al-Maghrabi JA; Butt NS; Anfinan N; Sait K; Sait H; Bajouh O; Khabaz MN
Acta Histochem; 2016 May; 118(4):430-4. PubMed ID: 27079858
[TBL] [Abstract][Full Text] [Related]
14. Shadow cell differentiation from squamoid morule in endometrial adenoacanthoma.
Nakamura T
Int J Clin Exp Pathol; 2015; 8(10):13120-4. PubMed ID: 26722510
[TBL] [Abstract][Full Text] [Related]
15. Primary Endometrial Yolk Sac Tumor With Endodermal-Intestinal Differentiation Masquerading as Metastatic Colorectal Adenocarcinoma.
Damato S; Haldar K; McCluggage WG
Int J Gynecol Pathol; 2016 Jul; 35(4):316-20. PubMed ID: 26598980
[TBL] [Abstract][Full Text] [Related]
16. PINCH protein expression in normal endometrium, atypical endometrial hyperplasia and endometrioid endometrial carcinoma.
Zhang HZ; Li XH; Zhang X; Zhang ZY; Meng YL; Xu SW; Zheng Y; Zhu ZL; Cui DS; Huang LX; Yan BY; Sun XF
Chemotherapy; 2010; 56(4):291-7. PubMed ID: 20714146
[TBL] [Abstract][Full Text] [Related]
17. Comparison of E-cadherin with STAT3 and apoptosis regulators: Bak and Bcl-xL in endometrioid adenocarcinomas of different ER-alpha immunoprofile.
Sulkowska U; Wincewicz A; Kanczuga-Koda L; Koda M; Sulkowski S
Gynecol Endocrinol; 2018 Feb; 34(2):171-174. PubMed ID: 28937296
[TBL] [Abstract][Full Text] [Related]
18. Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium.
Lawrenson K; Pakzamir E; Liu B; Lee JM; Delgado MK; Duncan K; Gayther SA; Liu S; Roman L; Mhawech-Fauceglia P
PLoS One; 2015; 10(7):e0130909. PubMed ID: 26132201
[TBL] [Abstract][Full Text] [Related]
19. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
20. Letter to the editor in response to "Stage 1, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence".
Pollock J
Gynecol Oncol; 2010 Jun; 117(3):507; author reply 507-8. PubMed ID: 20189231
[No Abstract] [Full Text] [Related]
[Next] [New Search]
